FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 11th, 2024 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations
This Fifth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of March 6, 2024, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders party hereto from time to time including OXFORD FINANCE CREDIT FUND II, LP, by its manager Oxford Finance Advisors, LLC (“Credit Fund II”), OXFORD FINANCE CREDIT FUND III, LP, by its manager Oxford Finance Advisors, LLC (“Credit Fund III”), OXFORD FINANCE FUNDING IX, LLC (“Funding IX”), OXFORD FINANCE FUNDING XIII, LLC (“Funding XIII”), and OXFORD FINANCE FUNDING 2023-1, LLC (“Funding 2023-1”; together with Credit Fund II, Credit Fund III, Funding IX, and Funding XIII, each a “Lender” and collectively, the “Lenders”), LEXICON PHARMACEUTICALS, INC. (“Parent”) and LEXICON PHARMACEUTICALS (NEW JERSEY), INC. (“Lex-NJ”), each a Delaware corporation with
PREFERRED STOCK PURCHASE AGREEMENT dated as of March 11, 2024 by and among LEXICON PHARMACEUTICALS, INC. and THE PURCHASERS PARTY HERETOPreferred Stock Purchase Agreement • March 11th, 2024 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of March 11, 2024 (the “Execution Date”), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on Exhibit A attached hereto (each a “Purchaser” and collectively the “Purchasers”). Capitalized terms used but not defined have the meanings ascribed to them in Section 5.9 of this Agreement.
